-
-
Precision Health Ecosystem FutureTech A Kinase Inhibitor that Induces Degradation of MYC Oncoprotein
This technology is a development drug lead aiming to meet the medical needs of patients with small cell lung cancer. Through disturbing MYC-Aurora A interaction and inducing degradation of MYC oncoprotein, this bioavailable kinase inhibitor could serve as a potential treatment entity for SCLC.
-
-
-
Precision Health Ecosystem FutureTech BPRSJ338: Therapeutic Applications for COVID-19
BPRSJ338 exhibits high potency of anti-SARS-CoV-2 activity and is in development for fighting COVID-19 as a first-in-class drug. BPRSJ338 also potently inhibits against broad-spectrum coronaviruses including SARS-CoV-2, SARS-CoV, HCoV-229E, HCoV-OC43, TGEV, FIPV and MHV. Related US and Taiwan patents have been granted. Therefore it is also applicable to fight against severe evolving coronaviruses in the future.
-
-
-
Bio-tech & New Drugs FutureTech Finding cures – New platformtechniques for the developmenttesting of new drugs for ataxia
Our inter-institutional research team developed RS-D7, a novel NMDAR modulator/DAO inhibitor as a drug candidate for the treatment of ataxia/MSA. Based upon the core symptoms, we designedapplied preclinical mouse behavioral phenotyping techniquesclinical motor assessments to demonstrate the effectiveness of RS-D7our functional assays. RS-D7 offers multi-symptomatic relief.
-
- 1
